drugset / Trial / NCT00334568

Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease

NCT00334568

Phase 2 Terminated 12 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

Clinical features in patients with the familial early onset forms and the sporadic forms of Alzheimers disease are similar, although the course of deterioration may be different. It would be very informative to examine the drug response of patients with Alzheimers disease by a certain genotype to find evidence favouring genotype-specific drug responses that may indicate genetically defined phenotypic differences in alzheimers disease.

Timeline

Start
2004-12
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule Oral

Indications